Shanghai Pharmaceutical announced the Shanghai Frontier, an innovative pharmaceutical park co-founded with top universities and top scientific research institutions. Shanghai Frontier focuses on cutting-edge biotechnologies such as gene cell therapy, nucleic acid drugs, and conjugated drugs to fill gaps in clinical needs in major diseases such as autoimmune diseases, oncology, neurological diseases, and rare diseases, and promote the introduction, incubation and commercialization of innovative projects. The Shanghai Frontier Park is about to open in September. It has already attracted many enterprises and institutions such as national key research institutes, Bayer of Germany, SDIC, Shanghai Biomedical Fund, and Ziyao Biotech.